Aurobindo to acquire under development product, related assets from Advent for Rs 90 crore
New Delhi: Drug firm Aurobindo Pharma has recently stated that its arm in the USA has signed a pact to acquire an under-development product and certain related assets from Australian Advent Pharmaceuticals Pty Ltd for USD 12.5 million, i.e. Rs 90.4 crore.
The company's wholly owned subsidiary, Aurobindo Pharma USA Inc, has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty Ltd, Australia, through its subsidiary AuroScience Pty Ltd Melbourne, Aurobindo Pharma said in a filing to BSE.
The acquisition is for a cash consideration of USD 12.5 million, it added.
The indicative time period for completion of the acquisition is January 2019, Aurobindo Pharma said.
The acquisition provides an opportunity to acquire assets that would be used for speciality generics business.
Read Also: Aurobindo Pharma Issues Voluntary Recall of Irbesartan Drug: FDA
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd